List of Excipients in Branded Drug ESZOPICLONE

« Back to Dashboard

Generic Drugs Containing ESZOPICLONE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	eszopiclone	0093-5537	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Teva Pharmaceuticals USA Inc	eszopiclone	0093-5537	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	eszopiclone	0093-5537	CROSCARMELLOSE SODIUM
Teva Pharmaceuticals USA Inc	eszopiclone	0093-5537	FD&C BLUE NO. 1 ALUMINUM LAKE

What are the Most Frequently-Used Excipients in ESZOPICLONE?

# Of NDCs	Excipient
32	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
24	ANHYDROUS LACTOSE
3	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
15	CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE

Eszopiclone Excipient Strategy and Commercial Opportunities

Last updated: October 18, 2026

Eszopiclone is a mature, immediate-release small-molecule hypnotic with broad generic availability and limited remaining composition-of-matter exclusivity. The strongest commercial opportunities are differentiated oral products rather than new chemical-entity protection. High-value targets include orally disintegrating tablets, low-dose pediatric or geriatric presentations, lactose-free formulations, taste-masked products, abuse-deterrent systems, and manufacturing platforms that improve content uniformity at 1 mg strength.

What is the current FDA and commercial status of eszopiclone?

Eszopiclone is the active S-enantiomer of zopiclone and is marketed in the United States under the brand name Lunesta. It is approved for the treatment of insomnia and is available in 1 mg, 2 mg, and 3 mg tablets. The drug is classified as a Schedule IV controlled substance in the United States.[1]

Attribute	Eszopiclone
Reference product	Lunesta
Innovator	Sepracor, later acquired by Sunovion Pharmaceuticals
Active ingredient	Eszopiclone
Dosage form	Immediate-release film-coated tablet
Strengths	1 mg, 2 mg, 3 mg
FDA therapeutic category	Sedative-hypnotic
Controlled-substance status	Schedule IV
Primary use	Insomnia
Generic pathway	Abbreviated New Drug Application, or ANDA
Biosimilar exposure	None
Key commercial issue	Generic price competition and controlled-substance compliance

The FDA labeling includes a boxed warning for complex sleep behaviors, including sleepwalking, sleep driving, and other activities performed while not fully awake. The warning applies to eszopiclone and other nonbenzodiazepine hypnotics.[1]

Generic competition has materially reduced the strategic value of the original brand formulation. Commercial returns now depend on manufacturing cost, distribution access, differentiated dosage forms, regulatory positioning, and control of specialized excipient or delivery technology.

What patents protect eszopiclone?

The principal historical patent covering eszopiclone was U.S. Patent No. 6,319,926, assigned to Sepracor. The patent covered cyclopyrrolone derivatives, including eszopiclone, and was listed in the FDA Orange Book for Lunesta.[2][3]

Patent	Subject matter	Historical assignee	Listed expiration
U.S. 6,319,926	Cyclopyrrolone derivatives, including eszopiclone	Sepracor	March 4, 2023

The expiration date may have been affected by applicable pediatric exclusivity or regulatory adjustments. The core patent term is no longer a meaningful barrier to ordinary generic eszopiclone tablets.

Patent protection for a new eszopiclone product would need to focus on one or more of the following:

• A novel dosage form, such as an orally disintegrating tablet.
• A controlled-release or biphasic release profile.
• A specific excipient combination that produces a defined dissolution profile.
• A taste-masking system.
• A low-dose formulation with improved content uniformity.
• A fixed-dose combination or a new therapeutic use.
• A manufacturing process that produces a distinctive solid-state or particle-size profile.

A formulation patent must provide a measurable technical advantage. Claims directed only to routine tablet excipients are vulnerable to obviousness challenges, particularly for a mature active pharmaceutical ingredient.

When did eszopiclone lose exclusivity?

The principal eszopiclone patent expired in 2023. Generic eszopiclone products entered the market before that date through FDA approval and patent litigation or settlement mechanisms associated with ANDA filings.

Exclusivity timeline

Event	Approximate timing
Sepracor develops and commercializes eszopiclone	Early 2000s
Lunesta FDA approval	December 2004
Core composition patent issued	March 2002
Generic ANDA litigation period	2010s
Generic approvals and market entry	2014 onward
Core patent expiration	March 4, 2023
Current market structure	Generic-dominated

The relevant commercial distinction is between FDA approval and commercial launch. An ANDA applicant may obtain approval before a patent expires but remain subject to a launch restriction under a settlement, court order, or statutory exclusivity period.

What is the Orange Book status of eszopiclone?

The Orange Book historically listed U.S. Patent No. 6,319,926 for Lunesta. Because that patent has expired, it does not provide a current blocking right against ordinary generic eszopiclone tablets.[2]

The Orange Book does not capture every possible commercial barrier. It is principally relevant to patents submitted for approved drug products and listed under FDA rules. Separate formulation, manufacturing, packaging, trademark, trade-secret, and contractual rights may affect a competing product without appearing as a blocking Orange Book patent.

Paragraph IV challenges

Generic applicants could challenge the listed Lunesta patent through Paragraph IV certifications. A Paragraph IV certification asserts that the listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

For a mature product such as eszopiclone, the principal Paragraph IV issues would include:

1. Validity of the compound claims.
2. Scope of claims covering the S-enantiomer.
3. Obviousness based on the known racemate and chiral separation literature.
4. Patent-term calculation.
5. Infringement based on the proposed generic formulation.

Because the principal patent has expired, future Paragraph IV risk is more relevant to newly patented formulations than to standard generic tablets.

What excipients are used in eszopiclone tablets?

Lunesta tablets use conventional immediate-release excipients. Public labeling identifies excipient classes including lactose monohydrate, maize starch, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, talc, and tablet colorants, with composition varying by strength.[1]

Excipient class	Functional role	Relevance to eszopiclone
Lactose monohydrate	Diluent	Supports tablet mass and compressibility
Maize starch	Binder or disintegrant	Supports granulation and breakup
Croscarmellose sodium	Superdisintegrant	Promotes rapid tablet disintegration
Colloidal silicon dioxide	Glidant	Improves powder flow
Magnesium stearate	Lubricant	Reduces tooling friction
Talc	Anti-adherent or coating aid	Supports film-coating performance
Colorants	Product identification	Differentiates 1 mg, 2 mg, and 3 mg strengths

Eszopiclone is administered at low milligram quantities, making blend uniformity and segregation control important. The 1 mg tablet is the most technically demanding strength because the active represents a small fraction of total tablet weight.

What excipient strategies offer the strongest commercial opportunity?

Low-dose content-uniformity platforms

The highest-volume generic opportunity remains a cost-efficient immediate-release tablet. A supplier or manufacturer can differentiate through:

• Ordered mixing of eszopiclone onto a carrier excipient.
• Spray-dried active-excipient composites.
• Controlled particle-size distribution.
• Low-shear blending that limits segregation.
• Continuous manufacturing with in-line assay monitoring.
• Direct compression using engineered lactose or co-processed excipients.

These approaches may improve batch reproducibility without changing the approved dosage form. A process patent is more credible when it links a defined manufacturing parameter to a demonstrated content-uniformity or dissolution benefit.

Lactose-free formulations

Lactose-free tablets could address patients with lactose intolerance, excipient avoidance preferences, or procurement requirements. Suitable alternatives include:

• Mannitol.
• Microcrystalline cellulose.
• Dibasic calcium phosphate.
• Isomalt.
• Pregelatinized starch.

The principal development risks are tablet size, friability, moisture sensitivity, and dissolution changes. A lactose-free product would generally remain an ANDA product if it is pharmaceutically equivalent and uses inactive ingredients permitted under FDA requirements.

Orally disintegrating tablets

An orally disintegrating tablet could improve administration for patients who have difficulty swallowing or who take medication during nighttime awakenings. Candidate excipient systems include mannitol, crospovidone, low-substituted hydroxypropyl cellulose, silicified microcrystalline cellulose, and flavoring or taste-masking agents.

Eszopiclone has a bitter or unpleasant taste profile that creates a central development issue. Effective approaches include:

• Polymer coating of active particles.
• Ion-exchange resin complexes.
• Lipid or wax barriers.
• Cyclodextrin complexes.
• Multiparticulate ODTs.
• Sweetener and flavor systems that reduce aftertaste.

A taste-masked ODT may support a 505(b)(2) strategy if the product claims a clinically meaningful administration advantage or a materially different pharmacokinetic profile. If the product is merely an equivalent dosage form, an ANDA may be more appropriate.

Abuse-deterrent formulations

Eszopiclone is Schedule IV, so abuse-deterrent technology has commercial relevance, although the abuse liability profile differs from that of opioids. Potential approaches include harder-to-crush tablets, aversive excipients, extended-release matrices, and tamper-resistant packaging.

The FDA’s abuse-deterrence framework is more developed for opioids than for hypnotics. A company would need evidence that the technology addresses a meaningful abuse route and provides a clinical or public-health advantage. Packaging and controlled-substance supply-chain controls may deliver a better risk-adjusted return than a complex abuse-deterrent tablet.

Modified-release formulations

A controlled-release product could target sleep maintenance while reducing rapid peak exposure. Potential commercial claims could focus on:

• Reduced early-morning rebound insomnia.
• Longer duration of hypnotic effect.
• Lower peak plasma concentration.
• Reduced next-day impairment.
• More consistent overnight exposure.

Modified release also creates regulatory and clinical risk. Eszopiclone labeling includes warnings regarding next-day impairment and complex sleep behaviors. A product that extends exposure could worsen those concerns unless supported by robust pharmacokinetic and clinical data.

What formulation patents could protect eszopiclone products?

The most defensible formulation claims would define a combination of composition and performance. Examples include:

Patent strategy	Potential claim focus	Commercial strength
Taste-masked particles	Coating thickness, polymer ratio, dissolution trigger	Moderate to strong if technically distinctive
ODT	Disintegration time, hardness, taste profile	Moderate
Low-dose tablet	Active distribution and content uniformity	Moderate
Modified release	Matrix composition and dissolution profile	Stronger, but higher development cost
Solid dispersion	Amorphous content and stabilizer ratio	Moderate
Co-processed excipient	Defined carrier structure and manufacturing method	Moderate
Packaging	Child resistance, unit-dose control, tamper evidence	Usually limited patent value

Broad claims such as “eszopiclone with a pharmaceutically acceptable excipient” are unlikely to provide durable protection. Narrower claims tied to dissolution, pharmacokinetics, sensory performance, or manufacturing reproducibility are more commercially useful.

How does eszopiclone compare with competing insomnia drugs?

Eszopiclone competes with zolpidem, zaleplon, doxepin, suvorexant, daridorexant, ramelteon, and generic sedating antidepressants. The competitive position depends on treatment duration, next-day impairment, controlled-substance status, price, and prescriber familiarity.

Product	Drug class	Controlled substance	Generic pressure	Excipient opportunity
Eszopiclone	Cyclopyrrolone hypnotic	Yes, Schedule IV	High	ODT, taste masking, low-dose precision
Zolpidem	Imidazopyridine hypnotic	Yes, Schedule IV	High	Modified release and sublingual delivery
Zaleplon	Pyrazolopyrimidine hypnotic	Yes, Schedule IV	High	Rapid-disintegration and short-duration products
Doxepin	Tricyclic antidepressant	No	High	Low-dose liquid and controlled release
Ramelteon	Melatonin receptor agonist	No	High	Pediatric, liquid, and ODT formats
Suvorexant	Orexin antagonist	Yes, Schedule IV	Lower than eszopiclone historically	Modified release and combination products
Daridorexant	Orexin antagonist	Yes, Schedule IV	Limited relative to mature generics	Novel delivery and dose optimization

Eszopiclone’s principal advantage is established clinical use and generic affordability. Its principal disadvantages are controlled-substance restrictions, next-day impairment concerns, and limited room for price premiums.

What generic launch risks exist for eszopiclone?

Generic launch risk is relatively low for a conventional immediate-release tablet because the core patent has expired and the reference product has an established regulatory history. The main risks are operational and commercial:

• Failure to match dissolution across strengths.
• Content-uniformity failures at 1 mg.
• Colorant or excipient differences requiring FDA justification.
• Controlled-substance quota and distribution controls.
• Price erosion from multiple ANDA holders.
• Product liability related to complex sleep behaviors.
• Manufacturing interruption caused by a single-source excipient.
• Inability to secure retail or institutional formulary access.

A differentiated product faces higher regulatory risk if it changes release characteristics, exposure, taste, or administration route.

Which companies are positioned to challenge or supply eszopiclone?

The generic market includes large manufacturers with established controlled-substance infrastructure, such as Teva, Viatris, Dr. Reddy’s Laboratories, Lupin, Zydus, and other ANDA sponsors. The precise active supplier set changes as approvals, commercial agreements, and discontinuations evolve.

Commercial opportunities exist for:

• Excipient manufacturers supplying engineered direct-compression grades.
• Taste-masking technology licensors.
• CDMOs with controlled-substance handling capability.
• Contract packagers offering unit-dose and tamper-evident formats.
• Specialty generic companies pursuing ODT or 505(b)(2) products.
• Analytical laboratories supporting dissolution, impurity, and extractables studies.

Licensing value is highest for a platform that can be applied to several hypnotics rather than eszopiclone alone. A single-product eszopiclone license has limited negotiating leverage unless it includes a defensible patent family, clinical differentiation, or an exclusive manufacturing advantage.

What is the geographic opportunity for eszopiclone excipients?

The United States offers the clearest opportunity for differentiated products because FDA-approved strengths, Orange Book history, and generic substitution create a defined regulatory pathway. Europe and other markets may support separate opportunities in:

• Orodispersible tablets.
• Unit-dose packaging.
• Lactose-free products.
• Hospital and elderly-care formulations.
• Products for swallowing difficulty.
• Local-language taste-masked presentations.

Geographic patent value will depend on whether formulation claims were filed before public disclosure and whether national patent terms remain active. Expired U.S. compound protection does not eliminate the possibility of active formulation rights in other jurisdictions.

How strong is the eszopiclone patent estate?

The legacy compound patent estate is weak as a current commercial barrier because the primary patent term has ended. A new eszopiclone product could still obtain meaningful protection, but only through a narrow and technically supported formulation or manufacturing estate.

A strong modern estate would include:

1. Composition claims covering the differentiated product.
2. Process claims covering a non-routine manufacturing step.
3. Method-of-use claims tied to a specific patient population.
4. Dissolution or pharmacokinetic limitations that are difficult to design around.
5. Multiple jurisdictions with synchronized filing and prosecution.
6. Trade-secret protection for process parameters and scale-up controls.

The commercial case should be based on product differentiation, not on the assumption that the historical Lunesta patent can block generic entry.

Key Takeaways

• Eszopiclone is a mature generic hypnotic with expired core patent protection.
• The principal historical patent was U.S. Patent No. 6,319,926, listed for Lunesta and expiring in 2023.
• Conventional tablets face intense price competition and have limited patent value.
• The strongest excipient opportunities are ODTs, taste masking, lactose-free products, and low-dose content-uniformity systems.
• Modified-release products could create greater differentiation but require more extensive pharmacokinetic and clinical development.
• The 1 mg strength creates a meaningful manufacturing opportunity because low active loading increases blend-uniformity risk.
• Biosimilar risk does not apply because eszopiclone is a small molecule.
• Controlled-substance handling, complex sleep-behavior warnings, and next-day impairment are central regulatory and liability issues.
• A platform license covering several sedative-hypnotics is likely to have greater commercial value than a single-product eszopiclone license.
• New patent value will depend on measurable technical performance, not routine excipient selection.

FAQs About Eszopiclone Excipient and Patent Opportunities

Can mannitol replace lactose in eszopiclone tablets?

Yes. Mannitol can replace lactose as a diluent, particularly in orally disintegrating or lactose-free products. The formulation must be requalified for hardness, friability, disintegration, dissolution, stability, and content uniformity.

Is an eszopiclone orally disintegrating tablet eligible for an ANDA?

It may be eligible for an ANDA if it demonstrates pharmaceutical equivalence and satisfies FDA requirements for the dosage form. A materially different pharmacokinetic profile or clinical use could support a 505(b)(2) pathway instead.

Can a taste-masked eszopiclone product receive new patent protection?

Yes. Patentability is more credible when the product includes a novel coating, resin complex, solid dispersion, or multiparticulate system with demonstrated taste, dissolution, stability, or pharmacokinetic advantages.

Does eszopiclone require special excipient controls because it is Schedule IV?

The excipients do not create the controlled-substance status. The active ingredient and finished product require appropriate procurement, inventory, distribution, recordkeeping, and security controls under applicable controlled-substance rules.

Is there a biosimilar pathway for eszopiclone?

No. Eszopiclone is a chemically synthesized small molecule. Competing products are regulated principally through generic-drug pathways such as ANDAs, or through 505(b)(2) applications for materially differentiated products.

References

1. U.S. Food and Drug Administration. (2019). Lunesta prescribing information: Eszopiclone tablets. FDA.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
3. United States Patent and Trademark Office. (2002). U.S. Patent No. 6,319,926: Cyclopyrrolone derivatives. U.S. Department of Commerce.
4. U.S. Food and Drug Administration. (2020). Product-specific guidance for eszopiclone tablets. FDA.
5. U.S. Drug Enforcement Administration. (2024). Controlled substances schedules. U.S. Department of Justice.